Ticlopidine

CHEMBL833 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

263.8 g/mol

LogP

3.6

Phase

4

This antiplatelet medication reduces the risk of stroke in patients who have had a previous stroke or TIA (mini-stroke) and cannot take aspirin. It works by blocking ADP-mediated platelet aggregation, preventing blood clots from forming. Its use has declined due to serious side effects including low white blood cell count and a rare but dangerous blood disorder (TTP), and it has largely been replaced by newer agents.

Masse moléculaire

263,8000 g/mol

LogP

3,60

TPSA

31,50 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Pancreatic Cancer Cardiovascular Disease Age-Related Macular Degeneration Asthma Chronic Obstructive Pulmonary Disease Migraine Systemic Lupus Erythematosus Chronic Kidney Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Type 2 Diabetes Hypertension Major Depressive Disorder HIV/AIDS Heart Failure Atrial Fibrillation

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Clc1ccccc1CN1CCc2sccc2C1

InChI

InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2

Molecular Formula

C14H14ClNS

HBD / HBA

- / 2

Liaisons Rotatives

2

Atomes Lourds

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This antiplatelet medication reduces the risk of stroke in patients who have had a previous stroke or TIA (mini-stroke) and cannot take aspirin. It works by blocking ADP-mediated platelet aggregation, preventing blood clots from forming. Its use has declined due to serious side effects including low white blood cell count and a rare but dangerous blood disorder (TTP), and it has largely been replaced by newer agents.

Yes, Ticlopidine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL833. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5472. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Ticlopidine sur PillFYI

Structure

Données Clés

Formule: C14H14ClNS

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.